Related Experiment Video
Updated: Jan 25, 2026

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro
Published on: January 9, 2018
Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy
Shuanghui Yang1,2, Jianguo Wen2, Huan Li2,3
1Department of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Abstract:
Natural killer (NK) cells are a key component of the innate immune system as they can attack cancer cells without prior sensitization. However, due to lack of cell-specific receptors, NK cells are not innately able to perform targeted cancer immunotherapy. Aptamers are short single-stranded oligonucleotides that specifically recognize their targets with high affinity in a similar manner to antibodies. To render NK cells with target-specificity, synthetic CD30-specific aptamers are anchored on cell surfaces to produce aptamer-engineered NK cells (ApEn-NK) without genetic alteration or cell damage. Under surface-anchored aptamer guidance, ApEn-NK specifically bind to CD30-expressing lymphoma cells but do not react to off-target cells. The resulting specific cell binding of ApEn-NK triggers higher apoptosis/death rates of lymphoma cells compared to parental NK cells. Additionally, experiments with primary human NK cells demonstrate the potential of ApEn-NK to specifically target and kill lymphoma cells, thus presenting a potential new approach for targeted immunotherapy by NK cells.
Insights
Natural killer (NK) cells engineered with aptamers (ApEn-NK) can specifically target and kill lymphoma cells. This novel approach enhances targeted cancer immunotherapy without genetic modification.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Natural killer (NK) cells are crucial for innate immunity against cancer but lack inherent target specificity for immunotherapy.
- Aptamers, oligonucleotide analogs of antibodies, offer high affinity and specificity for target recognition.
Purpose of the Study:
- To develop aptamer-engineered NK cells (ApEn-NK) for targeted cancer immunotherapy.
- To evaluate the efficacy of ApEn-NK in specifically binding and eliminating CD30-expressing lymphoma cells.
Main Methods:
- Synthetic CD30-specific aptamers were surface-anchored onto NK cells to create ApEn-NK without genetic alteration.
- ApEn-NK binding specificity and lymphoma cell apoptosis rates were assessed in vitro and with primary human NK cells.
Main Results:
- ApEn-NK demonstrated specific binding to CD30-expressing lymphoma cells, avoiding off-target interactions.
- ApEn-NK induced significantly higher apoptosis/death rates in lymphoma cells compared to unmodified NK cells.
- Experiments with primary human NK cells confirmed the targeted killing potential of ApEn-NK.
Conclusions:
- Aptamer engineering provides a non-genetic method to confer target specificity to NK cells.
- ApEn-NK represents a promising strategy for targeted immunotherapy of CD30-positive lymphomas.
- This approach holds potential for advancing NK cell-based cancer therapies.
Related Concept Videos
Natural Selection and Adaptation
Beyond physical adaptations,...
Cells of the Adaptive Immune Response
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cell Specific Gene Expression
Cell Specific Gene Expression
What is Natural Selection?

